Juzina

Sitagliptin, the active ingredient in Juzina, is a DPP-4 inhibitor presented as an oral tablet for oral administration. It works by enhancing the incretin system to improve glucose-dependent insulin secretion, thereby helping to control blood sugar levels in adults with type 2 diabetes mellitus.

GNH USA supplies Juzina as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides reliable logistics for global distribution. It operates across multiple regulatory markets to ensure consistent product availability.

Sitagliptin is used to manage hyperglycemia in the type 2 diabetes mellitus pathway.

- Type 2 diabetes mellitus: improves overall glycemic control by increasing insulin secretion in response to meals. - Adjunct therapy with metformin: enhances blood glucose lowering when combined with metformin. - Postprandial hyperglycemia: reduces post‑meal glucose spikes in patients with type 2 diabetes.

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: inflammation of the nose and throat lining. - Headache: mild to moderate head pain. - Diarrhea: loose, watery stools.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, potentially severe. - Severe allergic reactions: including rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia.

When prescribing Juzina, clinicians should consider several safety factors.

- Renal impairment: assess kidney function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes during therapy. - Concomitant insulin or sulfonylureas: increased risk of hypoglycemia; adjust doses accordingly. - Pregnancy and breastfeeding: safety not established; use only if clearly needed. - Cardiovascular disease: use with caution and monitor patient status. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Sitagliptin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Combination with insulin or sulfonylureas: may cause severe hypoglycemia; avoid unless dose is reduced. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): can increase sitagliptin exposure; avoid co-administration.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin plasma concentrations, potentially decreasing efficacy. - Diuretics (e.g., thiazides): may increase serum creatinine; monitor renal function. - ACE inhibitors or ARBs: monitor renal function when used together.